Proactiveinvestors USA & Canada Ozop Surgical Corp. Proactiveinvestors USA & Canada Ozop Surgical Corp. RSS feed en Sun, 16 Jun 2019 21:51:29 -0400 Genera CMS (Proactiveinvestors) (Proactiveinvestors) <![CDATA[News - Ozop Surgical completes initial testing of its adjustable ALIF interbody spinal implant ]]> Ozop Surgical Corp. (OTCMKTS:OZSC) announced Monday it has completed initial testing of its adjustable ALIF interbody spinal implant.

The Florida-based company began development of the ALIF implant, which is short for enhanced expandable anterior lumbar interbody fusion, in 2018.

The ALIF implant allows the surgeon to expand it after insertion into a disc space, reducing operating times while providing a cost savings for the hospital.

READ: Ozop rises as company gives vision for minimally invasive spinal surgery

CEO Michael Chermak said the company is encouraged by the initial-testing results and has “incorporated several improvements into our next design.”

Once the testing is completed and a final designated accepted, Ozop plans to submit the final design to the US Food and Drug Administration within the next two years. 

“Developing an infinitely adjustable ALIF implant is a challenging design goal but the end outcome will allow the surgeon to ensure segmental stability and restore sagittal balance,” Chermak said. “We look forward to completing testing for FDA submission in the near future and hope to have our approval by the end of the year."

Ozop’s stock trades around $0.045 a share.

Contact the author:

Follow him on Twitter @PatrickMGraham

Mon, 03 Jun 2019 10:39:00 -0400
<![CDATA[News - Ozop Surgical moves to crack code of minimally invasive spine surgery ]]> Ozop Surgical Corp (OTCMKTS:OZSC) is working to realize the promise of minimally invasive spinal surgery for the millions of people suffering from severe back pain.

Over the past 20 years, minimally invasive surgery has transformed medical procedures ranging from gall bladder and appendix removal to valve replacement and bypass surgery to orthopedics procedures involving knees, shoulders and hips. For patients, the benefits include lower costs, fewer complications, faster recovery and less pain.

Spinal surgery has been a laggard, according to Ozop, because most procedures require the placement of relatively large objects such as screws or plates.

Other areas of interest for Ozop are neurological and pain-management procedures. The company also invents, designs, develops, manufactures and distributes endoscopic instruments, surgical implants, instrumentation and related technologies

Ozop’s key assets

A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology for minimally invasive spine surgery. (“BLIF” is pronounced “bee” and then “lif, which rhymes with “cliff.”)

Medical-quality balloons are routinely used for opening clogged arteries, repairing broken bones and other procedures. The advantage of a balloon is that it can be inserted into a small incision and then inflated to the proper size. 

With BLIF, according to Ozop, a needle or wire is used to get to a damaged disc. Once imaging confirms placement, a small tube is placed over the needle or wire. Through this portal, an endoscope can be used to view the disc and damaged tissue is removed. (The tube protects surrounding muscle and tissue are protected from damage by the tube.) 

Once the damaged material has been removed, the disc is measured and a balloon is inserted and filled with a hardening polymer. A surgeon can then fill in the area around the implant with bone graft to help promote fusion of the spine.

Expected milestones for Ozop’s BLIF technology include establishing an experienced team of surgeons and industry experts to hone the technique and then complete tests for submission to the Food and Drug Administration. 

In addition, the company has begun development of an enhanced expandable anterior lumbar interbody fusion (ALIF) implant, with initial designs and prototypes completed. This product, according to Ozop, is easier to insert and use than competing products.

The company expects to complete design and testing in the first half of 2019 and anticipates FDA approval in the second half.

Other products in the pipeline include visualization tools for minimally invasive surgery including light filtration and 3D technology.

Inflection points

Ozop started to gain momentum in February 2018, when its purchase of Spinus LLC for $782,289 gave the company the rights to what it says is a rich intellectual property portfolio as well as an FDA-approved line of spinal products.

Another big step came when the company went public in April 2018 through a reverse merger. The partner in the deal was a publicly traded entity that rented bicycles, Segways and related equipment in Lithuania. Last December, just several months after the reverse merger, Ozop was promoted to the OTCQB exchange, the second tier of the OTC Markets.

Serving as CEO is Michael Chermak, who assumed that role in September 2016 and owns an 18% stake in the company. He sold a company he founded, Healthdemographics Inc, to Medirisk, a Dutch company, in 1997. He continues to serve as managing director of Makena Investment Advisers LLC and as president of MD Capital Advisors Inc.

Ozop's biggest shareholder, with a 37% stake, is Eric Siu, who serves as the company’s director of endoscopic program development. Siu, according to Ozop, has spent more than a decade creating intellectual property and developing minimally invasive endoscopic products.

A recent addition to the executive team is Thomas McLeer, the company’s chief operating officer since October. His prior work includes serving as vice president of sales and marketing at Rockaway, New Jersey-based LinkSpine.

Contact Dennis Fitzgerald at

Thu, 28 Mar 2019 13:13:00 -0400
<![CDATA[News - Ozop rises as company gives vision for minimally invasive spinal surgery ]]> Ozop Surgical Corp (OTCMKTS:OZSC) rose Monday as the surgical device company said it is moving forward with its plans to use medical-quality balloons in minimally invasive spinal surgery.

The company said expected 2019-2020 milestones include establishing a team of surgeons and other experts in the development of Balloon Lumbar Interbody Fusion (BLIF) technology.

Shares of Ozop climbed 6.3% to $0.85 in Monday’s OTC Markets trading.

READ: Ozop Surgical recognized as a top 10 orthopedic products provider by Med Tech Outlook magazine

Ozop is also expecting to complete all necessary testing for Food and Drug Administration (FDA) submission in the next two years. Upon approval, the company plans to build sets, complete a robust training regimen and begin "an alpha launch at key centers."

In 2018, the company said it began development of an enhanced expandable anterior lumbar interbody fusion (ALIF) implant with initial designs and prototypes completed.

The company expects to complete design and testing in the first half of 2019 and expects FDA approval in the second half.

“We are happy with our accomplishments to date and realize we have a lot of work ahead of us to achieve our goals and objectives for 2019 and beyond,”  CEO Michael Chermak said in a statement. “I thank all of our shareholders and investors for the confidence they have shown in our company.”

He added that he looks forward to making “a significant impact” for people suffering from back pain as well as on the healthcare industry as a whole.

Contact Dennis Fitzgerald at

Mon, 18 Mar 2019 10:54:00 -0400
<![CDATA[News - Ozop Surgical recognized as a top 10 orthopedic products provider by Med Tech Outlook magazine ]]> Ozop Surgical Corp said Tuesday that it has been recognized as one of the Top 10 orthopedic products providers by Med Tech Outlook Magazine.

The West Palm Beach, Florida-based company is working on what it says is the next step in minimally invasive spine surgery. Its technology combines an endoscope with an inflatable implant placed inside the human body using a small incision.

"With our technology, the future of spine fusion surgeries would be through a puncture and then insertion of an inflatable interbody device," Ozop CEO Michael Chermak said in a statement.

READ: Collagen Solutions 'well on track' with plans for CE Mark 

The benefits of the technology, according to the company, are expected to include avoiding potential damage to critical anatomy, the necessity for full-body anesthesia and lengthy hospitalization.

Surgical costs and rehab time would be significantly reduced, according to Ozop.

"We take pride in honoring Ozop as one of the 10 companies,” Alex D'souza, managing Editor of MedTech Outlook, said.

Shares of Ozop dropped $0.04 to $0.66 in Monday’s OTC Markets trading.

Contact Dennis Fitzgerald at

Tue, 05 Mar 2019 10:14:00 -0500
<![CDATA[Media files - OZOP Surgical makes headway on bringing its spine implant tech to market ]]> Tue, 15 Jan 2019 09:34:00 -0500 <![CDATA[Media files - OZOP Surgical looks to revolutionize spinal surgery with their technology ]]> Tue, 04 Dec 2018 17:00:00 -0500